EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy

Fahimeh Baghaei iD, Zahra Hemmat iD, Amir Taherkhani iD, Setareh Shojaei iD, Ali Teimoori iD

Journal of Immunology Research · 2025

DOI: 10.1155/jimr/9126083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, 2025. Verfasst von Fahimeh Baghaei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Pathology, School of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir. Hauptthemen laut MEDLINE: Cancer Vaccines, Epitopes, T-Lymphocyte, Immunotherapy, Receptors, Urokinase Plasminogen Activator. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The urokinase plasminogen activator receptor (uPAR) plays a crucial role in cancer development and progression, making it an attractive target for immunotherapeutic strategies. This study aimed to develop a multiepitope vaccine targeting uPAR by incorporating T cell epitopes and a toll‐like receptor 4 (TLR4) agonist as an adjuvant.

Methods

Immunoinformatics approaches were employed to predict and select immunogenic epitopes from the uPAR protein sequence. The selected epitopes were assembled into a multiepitope vaccine construct, including a TLR4 agonist derived from Mycobacterium tuberculosis as an adjuvant. The vaccine candidate underwent comprehensive in silico analyses, including antigenicity, allergenicity, physicochemical properties, and structural modeling. Molecular docking and molecular dynamics (MD) simulations were performed to evaluate the vaccine’s interaction with the TLR4 receptor and assess its structural stability. Also, vector design was performed using the SnapGene software, while immune response simulations were conducted with the C‐ImmSim server.

Results

The multiepitope vaccine construct comprised five cytotoxic T lymphocyte (CTL) epitopes, five helper T lymphocyte (HTL) epitopes, and the TLR4 agonist adjuvant. The vaccine was predicted to be nonallergenic, antigenic, and soluble, with favorable physicochemical properties. Molecular docking analysis revealed a strong binding affinity between the vaccine and TLR4, with a docking score of −334.37kcal/mol. MD simulations demonstrated the structural stability and rigidity of the vaccine–TLR4 complex. The computational immune simulation predicted a strong vaccine response with lasting antibody production, robust cellular immunity, and immunological memory formation.

Conclusion

The proposed multiepitope vaccine construct, consisting of carefully selected uPAR epitopes and a potent adjuvant, exhibits promising characteristics for inducing a robust immune response against cancer cells expressing uPAR. The favorable in silico results warrant further experimental validation and preclinical studies to assess the vaccine’s efficacy and potential as a cancer immunotherapeutic agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesEpitopes, T-LymphocyteImmunotherapyReceptors, Urokinase Plasminogen ActivatorNeoplasmsHumansMolecular Docking SimulationToll-Like Receptor 4Molecular Dynamics SimulationAdjuvants, ImmunologicComputer SimulationMycobacterium tuberculosisComputational Biology

Stichwörter der Autor:innen

TLR4cancerimmunotherapymultiepitopeuPARvaccine

Substanzen

Cancer VaccinesEpitopes, T-LymphocyteToll-Like Receptor 4Receptors, Urokinase Plasminogen ActivatorAdjuvants, ImmunologicTLR4 protein, human

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Pathology, School of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
  • Research Center for Molecular Medicine, Institute of Cancer, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
  • Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.

ORCID-Profile: Fahimeh Baghaei, Zahra Hemmat, Amir Taherkhani, Setareh Shojaei, Ali Teimoori

Zitieren

APA

Baghaei, F., Hemmat, Z., Taherkhani, A., Shojaei, S., & Teimoori, A. (2025). Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy. Journal of Immunology Research. https://doi.org/10.1155/jimr/9126083

Vancouver

Baghaei F, Hemmat Z, Taherkhani A, Shojaei S, Teimoori A. Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy. Journal of Immunology Research. 2025. doi:10.1155/jimr/9126083

BibTeX
@article{Baghaei2025,
  author = {Baghaei, Fahimeh and Hemmat, Zahra and Taherkhani, Amir and Shojaei, Setareh and Teimoori, Ali},
  title = {Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy},
  journal = {Journal of Immunology Research},
  year = {2025},
  doi = {10.1155/jimr/9126083}
}
Kostenlos starten →